AseBio
Registrarse
Registrarse
Registrarse

Capacidades de investigación y tecnológicasActualizado el 4 de mayo de 2026

Protein-only nanomaterial platforms

Communication Manager en NANBIOSIS-ICTS

Zaragoza, España

Acerca de

Advance in the life quality of patients is an essential purpose for biotechnology and nanomedicine. The development of highly tunable biomaterials suitable for therapeutic purposes perfectly matches the activity of the NANBIOSIS unit 1 PPP. In fact, recombinant proteins can be engineered to be used as effective, safe, non-invasive and cell selective nanomaterial in new therapeutic treatments. Protein-only nanostructures, either in soluble or Inclusion bodies form, have being successfully used both in human and animal health models, showing the highly potential and versatility of these nanomaterials.

Description

Soluble protein nanoparticles
The use of recombinant proteins to form nanostructures have generated high expectations because their potential applicability, especially in targeted drug delivery. In this context, a novel tunable platform of multifunctional soluble proteins, engineered to spontaneously self-assemble into nanostructures, has been shown to be an excellent model for newly therapeutic approaches.

Engineered multifunctional proteins are generally easy to produce and purify allowing an easy and time saving screening of different protein building blocks for a wide range of applicability.

Inclusion bodies
Insoluble protein aggregates, also known as Inclusion Bodies, long considered a discard product of recombinant protein production, are now being rediscovered for they application in animal and human health mainly for tissue regenerative processes. IBs in fact are non-soluble protein aggregates formed by active proteins which can be released from the IBs aggregates. These materials can be used both for decorating plastic supports in contact with cells, stimulating a cell response depending of the nature of the protein, or can be directly locally injected, providing a sustained release of active therapeutic protein, as it has been described for protein hormones accumulated in secretory granules of the endocrine system.
Once again, IBs are easy to produce, cost effective and almost every protein can be produce in this form.

More info: https://www.nanbiosis.es/protein-only-nanomaterial-platformfor-biomedical-purposes/

Tipo

  • Enfermedades genéticas y raras
  • Inmunología
  • Oncología

Organización

NANBIOSIS-ICTS

Valencia, España

Oportunidades similares

  • Capacidades de investigación y tecnológicas

    Proteomics: recombinant protein production, purification and characterization

    • Enzimas
    • Enfermedades infecciosas
    • Sistema respiratorio y pulmonar

    Gabriel Alfranca

    Communication Manager en NANBIOSIS-ICTS

    Zaragoza, España

  • Capacidades de investigación y tecnológicas

    Anti-peptide antibodies

    • Oncología
    • Inmunología
    • Detección de sustancias
    • Enfermedades infecciosas
    • Salud animal/Veterinaria

    Gabriel Alfranca

    Communication Manager en NANBIOSIS-ICTS

    Zaragoza, España

  • Producto

    CLICK’N CUT

    Rosa M Osuna Aguilar

    Business Development Manager en Biat Group

    Jerez de la Fra., España